Get started
Author

Scott D. Newsome

Observed name: Newsome, Scott D.
OpenAlex ID: A5136092477
Miv-cel CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person Syndrome in a Pivotal, Multicenter, Phase 2 Study (KYSA-8) (LS2.008)
2026 · Amanda L. Piquet, Anastasia Zekeridou, et al. · Neurology · 1
Ocrelizumab subcutaneous: final analysis of the OCARINA II study
2026 · Scott D. Newsome, Lawrence Goldstick, et al. · Multiple Sclerosis and Related Disorders
Risks and Benefits of Disease-Modifying Therapies in People Aging With Multiple Sclerosis
2026 · John R. Corboy, Sarah A. Morrow, et al. · International Journal of MS Care
PDF
Aging and Multiple Sclerosis: Multidisciplinary Care and Access to Care
2026 · Renee Stewart, Rachael Stacom, et al. · International Journal of MS Care
PDF
Comorbidity, Polypharmacy, and Aging in Multiple Sclerosis
2026 · Ruth Ann Marrie, Jacquelyn Bainbridge, et al. · International Journal of MS Care
Week 96 Analysis of the OCARINA II Study Characterizing Subcutaneous Ocrelizumab in Patients With Relapsing or Primary Progressive Multiple Sclerosis (P7-19.006)
2026 · Scott D. Newsome, Lawrence Goldstick, et al. · Neurology
Age-Related Changes in Multiple Sclerosis Pathophysiology and Clinical Function
2026 · Yinan Zhang, Patty Bobryk, et al. · International Journal of MS Care
Harmonizing MR Images Across 100+ Scanners: Multi-site Validation with Traveling Subjects and Real-world Protocols
2026 · Hays, Savannah P., Zuo, Lianrui, et al. · arXiv (Cornell University)
PDF
DICOM-CLIP: Zero-Shot Acquisition Parameter Retrieval from Unprocessed Dicom Files
2026 · Prahlad Anand, Aaron Carass, et al. · IEEE International Symposium on Biomedical Imaging (ISBI)
Ocrélizumab sous-cutané : analyse finale de l’étude OCARINA II
2026 · Olivier Guerrier, Scott D. Newsome, et al. · Revue Neurologique
Works count: 10
Citation count: 1
H-index: 1
I10-index:
Year
Topic
Type